Overview

MSB11022 in Healthy Subjects

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

This is a phase I, randomized, double-blind, parallel-group trial to compare Investigation Medicinal Product (IMP) MSB11022, US- Reference Product (RP), and EU- Reference Medicinal Product (RMP) (Humira®) in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Fresenius Kabi SwissBioSim GmbH

Treatments:

Adalimumab